Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.

P. B. Chapman; A. Hauschild; C. Robert; J. M. G. Larkin; J. B. A. G. Haanen; A. Ribas; D. Hogg; S. O'Day; P. A. Ascierto; A. Testori; P. Lorigan; R. Dummer; J. A. Sosman; C. Garbe; R. J. Lee; K. B. Nolop; B. Nelson; J. Hou; K. T. Flaherty; G. A. McArthur

Journal Article

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.

Chapman P
Hauschild A
Robert C
et al.

Journal of Clinical Oncology (2011) 29(15_suppl) LBA4-LBA4

DOI: 10.1200/jco.2011.29.15_suppl.lba4

N/ACitations

N/AReaders

Get full text

Cite

CITATION STYLE

APA

Chapman, P. B., Hauschild, A., Robert, C., Larkin, J. M. G., Haanen, J. B. A. G., Ribas, A., … McArthur, G. A. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas. Journal of Clinical Oncology, 29(15_suppl), LBA4–LBA4. https://doi.org/10.1200/jco.2011.29.15_suppl.lba4

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.

Cite

Register to see more suggestions